

Title (en)

MULTI-INDICATION MRNA CANCER IMMUNOTHERAPY

Title (de)

MRNA-KREBSIMMUNTHERAPIE MIT MEHREREN INDIKATIONEN

Title (fr)

IMMUNOTHÉRAPIE ANTICANCÉREUSE À BASE D'ARNM À INDICATIONS MULTIPLES

Publication

**EP 3618856 A4 20210224 (EN)**

Application

**EP 18795120 A 20180430**

Priority

- US 201715583599 A 20170501
- US 2018030142 W 20180430

Abstract (en)

[origin: WO2018204234A1] Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.

IPC 8 full level

**A61K 39/00** (2006.01); **A61K 39/02** (2006.01); **A61P 35/00** (2006.01); **C07H 21/02** (2006.01)

CPC (source: EP)

**A61K 39/02** (2013.01); **A61P 35/00** (2018.01); **A61K 2039/515** (2013.01); **A61K 2039/5152** (2013.01); **A61K 2039/53** (2013.01); **A61K 2039/54** (2013.01); **A61K 2039/80** (2018.08)

Citation (search report)

[I] WO 2016187407 A1 20161124 - MORPHOGENESIS INC [US]

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**WO 2018204234 A1 20181108**; EP 3618856 A1 20200311; EP 3618856 A4 20210224

DOCDB simple family (application)

**US 2018030142 W 20180430**; EP 18795120 A 20180430